共 35 条
- [32] Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE ProjectMICROORGANISMS, 2021, 9 (04)Bennett, Julia C.Hetrich, Marissa K.Quesada, Maria GarciaSinkevitch, Jenna N.Knoll, Maria DeloriaFeikin, Daniel R.Zeger, Scott L.Kagucia, Eunice W.Cohen, Adam L.Ampofo, KrowBrandileone, Maria-Cristina C.Bruden, DanaCamilli, RominaCastilla, JesusChan, GuanhaoCook, HeatherCornick, Jennifer E.Dagan, RonDalby, TineDanis, Kostasde Miguel, SaraDe Wals, PhilippeDesmet, StefanieGeorgakopoulou, TheanoGilkison, CharlotteGrgic-Vitek, MartaHammitt, Laura L.Hilty, MarkusHo, Pak-LeungJayasinghe, SanjayKellner, James D.Kleynhans, JackieKnol, Mirjam J.Kozakova, JanaKristinsson, Karl G.Ladhani, Shamez N.MacDonald, LauraMackenzie, Grant A.Mad'arova, LuciaMcGeer, AllisonMereckiene, JolitaMorfeldt, EvaMungun, TuyaMunoz-Almagro, CarmenNuorti, J. PekkaParagi, MetkaPilishvili, TamaraPuentes, RodrigoSaha, Samir K.Khan, Aalisha Sahu
- [33] A Population-Based Assessment of the Impact of 7-and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance MechanismsCLINICAL INFECTIOUS DISEASES, 2017, 65 (06) : 990 - 998Schroeder, Max R.Chancey, Scott T.Thomas, StephanieKuo, Wan-HsuanSatola, Sarah W.Farley, Monica M.Stephens, David S.
- [34] Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled studyEXPERT REVIEW OF VACCINES, 2025, 24 (01) : 121 - 127Izu, AlaneMutsaerts, Eleanora AmlOlwagen, CourtneyJose, LisaKoen, AnthonetNana, Amit J.Cutland, Clare L.Madhi, Shabir A.
- [35] Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian childrenVACCINE, 2023, 41 (19) : 3066 - 3079Kawade, AnandDayma, GirishApte, AditiTelang, NilimaSatpute, MeenakshiPearce, EmmaRoalfe, LucyPatil, RakeshWang, YanyunNoori, NavidehGondhali, ArunJuvekar, SanjayOron, Assaf P.Sanghavi, SonaliGoldblatt, DavidDagan, RonBavdekar, Ashish